GLP-2 Tablets

Description

---

Tirzepatide (Dual GLP-1/GIP Receptor Agonist / Incretin Pathway Modulator)

Form: Tablet
Concentration: 500 mcg per tablet
Quantity per Bottle: 25 tablets

Molecular Formula: C₂₂₅H₃₆₃N₄₈O₆₈
Molecular Weight: 4,814.55 g/mol
CAS Number: 2023788-19-2
Purity: ≥98% (HPLC)
Storage: Store in a cool, dry place away from light and moisture.

---

Description

Tirzepatide is a synthetic dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
It is a next-generation incretin mimetic that combines enhanced insulinotropic, lipolytic, and anorexigenic activity through co-activation of two incretin pathways.

Preclinical research shows that Tirzepatide promotes improved glucose tolerance, insulin sensitivity, and weight reduction by amplifying cAMP signaling and pancreatic β-cell responsiveness while reducing appetite and hepatic lipid synthesis.
It is a powerful model compound for studying dual incretin receptor pharmacology, energy balance, and metabolic signaling cross-talk.

---

Intended Use

This product is intended for laboratory research use only.
It is not for human consumption, diagnostic, or therapeutic applications.
All handling should be performed by qualified professionals in a controlled research environment.

---

Key Research Applications

• Investigation of dual GLP-1 and GIP receptor agonism and signal synergy

• Studies on glucose metabolism, insulin secretion, and adiposity regulation

• Research on energy expenditure, appetite modulation, and body-weight control

• Analysis of peptide-based incretin therapies and metabolic cross-pathway modulation